Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos.
Popular Articles

As The Market Potential Grows, Developers Press For Keys To Delivering Systemic Drugs Via Inhalation
At a time when the drug industry is striving for patient-friendly delivery methods for new and existing drugs, the growing availability of innovative inhaler device designs is driving interest in pulmonary drug delivery technology and devices as an alternative to oral and parenteral routes of administration. While well-established for treating upper respiratory diseases such as asthma and COPD, companies competing in the inhaled drug delivery sector - major players such as GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim as well as pure-play start-ups - continue to view delivery of systemic drugs via inhalation as a major opportunity.
pharmacy online
Redefining How A Chronic Auto-Immune Disease Is Diagnosed
New research from Jefferson Hospital for Neuroscience (JHN) may redefine how Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is diagnosed. Eduardo De Sousa, M.D., assistant professor of Neurology at Jefferson Medical College of Thomas Jefferson University, and director of the Electrodiagnostic Neuromuscular Lab at JHN, led the study which looked at the number of demyelinating features that are needed to differentiate between CIDP, Amyotrophic lateral sclerosis (ALS, or Lou Gehrig"s disease) and diabetic neuropathy. His research suggests a minimum number of three demyelinating features can be used to positively identify CIDP in a patient. CIDP is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. It affects about 50,000 people in the United States. The study, available in the current edition of the Journal of Clinical Neuromuscular Disease, may help doctors more effectively diagnose and treat CIDP.
News of the day
To Defeat Tuberculosis, Higher Drug Doses Needed
The typical dose of a medication considered pivotal in treating tuberculosis effectively is much too low to account for modern-day physiques, UT Southwestern Medical Center researchers said.
Sexual Health

Agendia To Present Multiple Predictive And Prognostic Studies On Breast And Colorectal Cancers At ASCO Annual Meeting

Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia, the University of California San Francisco and the Netherlands Cancer Institute will present data from multiple studies at the American Society of Clinical Oncology Annual Meeting, May 29 - June 2, 2009, in Orlando, Florida. The study results further underpin the broad predictive and prognostic power of Agendia"s breast cancer recurrence test MammaPrint(R) and highlight promising data on Agendia"s new colon cancer recurrence test, ColoPrint(TM). Visitors can meet the Agendia team in booth #2014 and study results will be discussed at the following sessions: Date: Saturday, May 30, 2009 ORAL PRESENTATION Abstract #512 Time: 5:00PM - 5:15PM Location: Level 2, West Hall D1 The 70-gene profile and chemotherapy benefit in 1,600 breast cancer patients R. A. Bender, M. Knauer, E. J. Rutgers, A. M. Glas, F. A. de Snoo, S. C. Linn, L. J. Van "t Veer Date: Saturday, May 30, 2009 ORAL PRESENTATION Abstract # LBA515 Time: 3:00PM - 6:00PM Location: Level 2, West Hall D1 Breast cancer molecular profiles predict tumor response of neoadjuvant Doxorubicin and Taxol, the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) L. J. Esserman, C. Perou, M. Cheang, A. DeMichele, L. Carey, L. J. van "t Veer, J. Gray, E. Petricoin, K. Conway, D. Berry, I-Spy Investigators Date: Saturday, May 30, 2009 POSTER PRESENTATION Abstract #6570 Time: 2:00PM - 6:00PM Location: Level 2, West Hall C Cost effectiveness of targeting chemotherapy with the 70-gene prognostic signature in early stage breast cancer (ESBC) patients K. B. Tong, E. Chen, G. Brink, R. Bender, F. de Snoo, J. Malin Date: Sunday, May 31, 2009 POSTER DISCUSSION Abstract #535 Time: 8:00AM - 12:00PM Location: Level 2, West Hall D1, W240A Outcome prediction by the 70-gene profile in the context of the National Comprehensive Cancer Network (NCCN) guideline F. A. de Snoo, M. Knauer, R. A. Bender, L. Stork-Sloots, E. J. Rutgers, A. M. Glas, S. C. Linn, L. J. Van "t Veer Date: Sunday, May 31, 2009 POSTER PRESENTATION Abstract #4036 Time: 8:00 AM - 12:00 PM Location: Level 2, West Hall C Development and validation of a robust prognostic and predictive signature for colorectal cancer (CRC) patients A. M. Glas, P. Roepman, R. Salazar, G. Capella, V. Moreno, J. Westerga, P. J. Kuppen, I. Simon, L. J. Van "t Veer, R. Tollenaar Date: Sunday, May 31, 2009 POSTER DISCUSSION Abstract #518 Time: 8:00AM - 12:00PM Location: Level 2, West Hall D1, W240A Early determination of metastatic potential in breast cancer: the 70-gene signature in small tumors M. Knauer, S. Mook, V. Retç¨l, M. Kok, J. Wesseling, A. M. Glas, E. J. Rutgers, L. J. van "t Veer, S. C. Linn Date: Monday, June 01, 2009 POSTER PRESENTATION Abstract #11083 Time: 1:00PM - 5:00PM Location: Level 2, West Hall C Combining multi-gene profiling of molecular subtypes with the 70-gene profile for classification of breast cancer L. Stork-Sloots, O. Krijgsman, P. Roepman, F. A. de Snoo, R. A. Bender, A. M. Glas About MammaPrint(R) MammaPrint is the first "in vitro diagnostic multivariate index assay" (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis-patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests. All MammaPrint tests are conducted in Agendia"s CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process. Agendia B.V.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009